In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Stands Firm Against Florida Price Negotiations

Executive Summary

Lilly turned its back on Florida's call for supplemental rebates on Zyprexa knowing that it was protected by the new Medicare law. The company eventually reached a deal with the state that allows for price flexibility and supports longer use of the drug. Manufacturers with drugs categorized under Medicare's six protected drug classes could do the same.

You may also be interested in...

Lilly's Zyprexa: A Victim of Its Past Success

Antipsychotics in general-and Lilly's Zyprexa in particular-may be the products taking the biggest hit from health care reform. The only thing worse was the alternative.

Pfizer's Lipitor Sees Big Boost From Medicare

Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.

Lilly Makes Part D Pay

Lilly is quietly acknowledging that there will be a pay off from the launch of the new Medicare prescription drug benefit, thanks to the shift of many Zyprexa patients away from the price controlled Medicaid market.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts